Brown Brothers Harriman & CO Bristol Myers Squibb CO Transaction History

Brown Brothers Harriman & CO

$12.7 Billion
Q2 2024

A detailed history of Brown Brothers Harriman & CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 93,540 shares of BMY stock, worth $4.98 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

93,540

Previous 95,551 2.1%

Holding current value

$4.98 Million

Previous $5.18 Million 25.03%

% of portfolio

0.03%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$40.25 - $52.99 $80,942 - $106,562	-2,011 Reduced 2.1%	93,540 $3.88 Million
Q1 2024 May 10, 2024	SELL	$47.98 - $54.4 $110,306 - $125,065	-2,299 Reduced 2.35%	95,551 $5.18 Million
Q4 2023 Feb 12, 2024	SELL	$48.48 - $57.85 $109,904 - $131,145	-2,267 Reduced 2.26%	97,850 $5.02 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $82,551 - $92,304	-1,426 Reduced 1.4%	100,117 $5.81 Million
Q2 2023 Aug 07, 2023	SELL	$63.71 - $70.74 $698,643 - $775,734	-10,966 Reduced 9.75%	101,543 $6.49 Million
Q1 2023 May 11, 2023	SELL	$65.71 - $74.53 $252,063 - $285,897	-3,836 Reduced 3.3%	112,509 $7.8 Million
Q4 2022 Feb 09, 2023	BUY	$68.48 - $81.09 $1.61 Million - $1.91 Million	23,525 Added 25.34%	116,345 $8.37 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $547 - $323,419	4,209 Added 4.75%	92,820 $6.6 Million
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $26,942 - $29,672	-371 Reduced 0.42%	88,611 $6.82 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $109,065 - $130,779	-1,774 Reduced 1.95%	88,982 $6.5 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $820,753 - $956,806	-15,304 Reduced 14.43%	90,756 $5.66 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $666,727 - $780,985	-11,268 Reduced 9.6%	106,060 $6.28 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $16,653 - $18,135	269 Added 0.23%	117,328 $7.84 Million
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $80,761 - $90,833	1,361 Added 1.18%	117,059 $7.39 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $171,891 - $194,785	2,977 Added 2.64%	115,698 $7.18 Million
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $131,629 - $145,862	-2,292 Reduced 1.99%	112,721 $6.8 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $446,015 - $521,436	-8,136 Reduced 6.61%	115,013 $6.76 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $424,745 - $617,254	9,154 Added 8.03%	123,149 $6.86 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $583,778 - $761,485	11,863 Added 11.62%	113,995 $7.32 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $283,051 - $335,598	6,618 Added 6.93%	102,132 $5.18 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $69,294 - $76,625	-1,553 Reduced 1.6%	95,514 $4.33 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $38,667 - $46,106	-857 Reduced 0.88%	97,067 $4.63 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $777,819 - $1.01 Million	15,952 Added 19.46%	97,924 $5.09 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $196,917 - $222,108	3,568 Added 4.55%	81,972 $5.09 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $630,159 - $785,423	-12,471 Reduced 13.72%	78,404 $4.34 Million
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $5,213 - $6,001	-87 Reduced 0.1%	90,875 $5.75 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $52,747 - $57,507	880 Added 0.98%	90,962 $5.57 Million
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $210,591 - $243,040	-3,813 Reduced 4.06%	90,082 $5.74 Million
Q2 2017 Aug 14, 2017	BUY	N/A	93,895	93,895 $5.23 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.

Account

Brown Brothers Harriman & CO Bristol Myers Squibb CO Transaction History